Anand P Chokkalingam
Overview
Explore the profile of Anand P Chokkalingam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fusco D, Malenica I, Gunthard H, Gupta S, Kurbegov D, Balani B, et al.
Clin Infect Dis
. 2024 Jun;
79(5):1182-1189.
PMID: 38920297
Background: Remdesivir, an RNA-polymerase prodrug inhibitor approved for treatment of coronavirus disease 2019 (COVID-19), shortens recovery time and improves clinical outcomes. This prespecified analysis compared remdesivir plus standard of care...
2.
Wang A, Shen J, Rodriguez A, Saunders E, Chen F, Janivara R, et al.
Nat Genet
. 2023 Nov;
55(12):2065-2074.
PMID: 37945903
The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry...
3.
Chen F, Madduri R, Rodriguez A, Darst B, Chou A, Sheng X, et al.
Eur Urol
. 2023 Mar;
84(1):13-21.
PMID: 36872133
Background: Genetic factors play an important role in prostate cancer (PCa) susceptibility. Objective: To discover common genetic variants contributing to the risk of PCa in men of African ancestry. Design,...
4.
Chokkalingam A, Hayden J, Goldman J, Li H, Asubonteng J, Mozaffari E, et al.
JAMA Netw Open
. 2022 Dec;
5(12):e2244505.
PMID: 36454570
Importance: SARS-CoV-2, which causes COVID-19, poses considerable morbidity and mortality risks. Studies using data collected during routine clinical practice can supplement randomized clinical trials to provide needed evidence, especially during...
5.
Kim W, Telep L, Chokkalingam A
Aliment Pharmacol Ther
. 2022 Apr;
55(10):1344-1345.
PMID: 35472178
No abstract available.
6.
Sulkowski M, Telep L, Colombo M, Durand F, Reddy K, Lawitz E, et al.
Aliment Pharmacol Ther
. 2022 Mar;
55(9):1169-1178.
PMID: 35235245
Background: Sofosbuvir, a prodrug nucleoside inhibitor of hepatitis C virus, has a predominant circulating metabolite that is renally eliminated. Whether sofosbuvir is associated with chronic kidney disease (CKD) progression is...
7.
Kim W, Telep L, Jump B, Lu M, Ramroth H, Flaherty J, et al.
Aliment Pharmacol Ther
. 2022 Feb;
55(7):828-835.
PMID: 35137422
Background: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the first-line treatment agents for chronic hepatitis B virus (HBV). Recently, whether the degree to which the risk of hepatocellular carcinoma...
8.
Darst B, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, et al.
Eur Urol
. 2022 Jan;
81(5):458-462.
PMID: 35031163
A rare African ancestry-specific germline deletion variant in HOXB13 (X285K, rs77179853) was recently reported in Martinican men with early-onset prostate cancer. Given the role of HOXB13 germline variation in prostate...
9.
Olender S, Walunas T, Martinez E, Perez K, Castagna A, Wang S, et al.
Open Forum Infect Dis
. 2021 Jul;
8(7):ofab278.
PMID: 34282406
Background: Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown to shorten time to...
10.
Goldman D, Aldrich M, Hagmann S, Bamford A, Camacho-Gonzalez A, Lapadula G, et al.
Pediatrics
. 2021 Apr;
147(5).
PMID: 33883243
Objectives: Remdesivir shortens time to recovery in adults with severe coronavirus disease 2019 (COVID-19), but its efficacy and safety in children are unknown. We describe outcomes in children with severe...